2.65
-0.01(-0.38%)
Currency In USD
Address
103 Montgomery Street
San Francisco, CA 94129
United States of America
Phone
858 299 4699
Website
Sector
Healthcare
Industry
Biotechnology
Employees
84
First IPO Date
December 03, 2020
| Name | Title | Pay | Year Born |
| Mr. Nima Farzan M.B.A. | President, Chief Executive Officer & Director | 891,954 | 1976 |
| Ms. Neha Krishnamohan | Chief Financial Officer, Principal Accounting Officer and Executive Vice President of Corporate Development | 548,950 | 1988 |
| Mr. Mark A. Meltz | Chief Operating Officer, General Counsel, Treasurer & Secretary | 671,864 | 1974 |
| Dr. Robert Kania Ph.D. | Senior Vice President of Research | 0 | N/A |
| Dr. Richard Thomas Williams MBBS, Ph.D. | Chief Medical Officer | 0 | 1969 |
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.